Study of Cilostazol to Prevent Delayed Cerebral Ischemia and Improve Neurological Outcomes in Adults with Aneurysmal Subarachnoid Hemorrhage
Led by Beijing Tiantan Hospital · Updated on 2026-10-16
380
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a multicenter randomized trial to evaluate whether cilostazol can reduce the risk of delayed cerebral ischemia DCI following aneurysmal subarachnoid hemorrhage aSAH and improve neurological outcomes. The study also aims to assess the safety of cilostazol in this patient population. This Phase 3 trial involves 316 patients from 30 hospitals in China, focusing on adults aged 18 to 80 years diagnosed with aSAH and treated within 72 hours of symptom onset.
Participants will be randomly assigned to one of two groups the experimental group will receive cilostazol 100 mg twice daily for 14 days alongside standard aSAH treatment, while the control group will receive a placebo twice daily for the same duration along with standard care. The treatments are administered within 24 hours after randomization. The trial is double-blinded and placebo-controlled to compare the effects of cilostazol versus placebo.
During the study, participants will be monitored for neurological function prognosis at 90 days after randomization, which is the primary outcome measure. Secondary outcomes include the occurrence of delayed cerebral ischemia within approximately 14 days, and the incidence of intracranial rebleeding or other severe bleeding events within 90 days. Participants will undergo assessments including imaging and clinical evaluations, with safety and efficacy monitored throughout the trial period lasting until the study completion date in August 2027.
CONDITIONS
Brief Title
Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage
Research Team
L
Liping Liu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with subarachnoid hemorrhage by CT scan with responsible aneurysm identified by CTA or DSA
Received aneurysm coil embolization or craniotomy clipping within 72 hours of symptom onset
Hunt-Hess grade II-IV
No rebleeding or new intracranial hemorrhage on head CT within 6 hours after surgery
Able to understand and follow study procedures and provide informed consent
You will not qualify if you...
More than one aneurysm confirmed by CTA or DSA
Modified Rankin Scale score 3 or higher before onset
Contraindications to cilostazol, including allergy, severe heart failure (NYHA Grade III or IV), coagulation disorders, systemic bleeding, pregnancy, or lactation
Severe organic diseases with expected survival less than 90 days
Severe liver or renal insufficiency before randomization
Aneurysm treatment requiring other antiplatelet drugs after intervention
Currently receiving other investigational drugs or device trials
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Treatment
Duration - 14 days
Participants receive either cilostazol 100 mg twice daily or placebo twice daily for 14 days along with standard aneurysmal subarachnoid hemorrhage treatment.
Daily dosing with regular monitoring visits during treatment
Follow-up
Duration - Approximately 90 days
Participants are monitored for neurological function and safety outcomes up to 90 days after randomization.
Regular follow-up visits with neurological assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of Molecular and Clinical Factors in Adults With Aneurysmal Subarachnoid Hemorrhage
Using Multi-Omics Analysis to Understand Complications and Outcomes
Study of Cilostazol to Prevent Delayed Cerebral Ischemia and Improve Neurological Outcomes in Adults with Aneurysmal Subarachnoid Hemorrhage
Study of Deferoxamine Treatment for Adults with Aneurysmal Subarachnoid Hemorrhage up to Age 80
Observational Study of Dome-Only Coiling Treatment in Adults with Severe Aneurysmal Subarachnoid Hemorrhage
Study of Early Lumbar Drainage with Intrathecal Urokinase Injection for Treating Severe Aneurysmal Subarachnoid Hemorrhage
Randomized Trial of Fludrocortisone Versus Placebo for Treatment in Adults With Aneurysmal Subarachnoid Hemorrhage in Critical Care
Randomized Study of Human Albumin Versus Standard Fluid Therapy for Improving Outcomes in Adults with Aneurysmal Subarachnoid Hemorrhage
Evaluating Higher Dose Nadroparin to Improve Survival and Outcomes
in Adults With Aneurysmal Subarachnoid Hemorrhage Treated by Endovascular Coiling
Long-term Outcomes of Emergency Treatment for Aneurysmal Subarachnoid Hemorrhage Using Surgery or Endovascular Coiling
Real-world Data Collection of Microvention Devices for Treating Intracranial Aneurysms and Acute Ischemic Stroke
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart Association/American Stroke Association.
Brian L Hoh, Nerissa U Ko, Sepideh Amin-Hanjani...